Hemophilia
We recommend
Results of Prophylactic Treatment of Severe von Willebrand Disease with Recombinant vWF
Níže citovaná studie fáze III hodnotila účinnost a bezpečnost 12měsíční profylaxe rekombinantním von Willebrandovým faktorem (rvWF) u 23 pacientů s těžkou von Willebrandovou chorobou (vWD), kteří byli dříve léčeni jen podle potřeby (při výskytu spontánního krvácení) nebo předtím užívali profylaxi vWF získaným z plazmy (pdvWF).
Smaller Volume and Faster Infusion Rate of aPCC: What Do Current Data Say About This Modification?
Podání infuze s koncentrátem aktivovaného protrombinového komplexu (aPCC) při standardizované…
Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment
With the development of new treatment options for hemophilia, there has also been progress in…
Articles on this topic
Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A
Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of…
Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A
Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the…
Pharmacokinetic Comparison of Two EHL Products in Hemophilia A
According to a Canadian study published last year, certain pharmacokinetic differences were…
Practical Two-Point Pharmacokinetic Protocol in Hemophilia A
A recently published study confirmed the practicality of a shortened and simple…
Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
The possibility of actively preventing severe bleeding after a major cardiac surgical…
Neutralizing Antibodies Against Emicizumab – Detailed Analysis Based on a Case Study
Japanese authors investigated the mechanism of reduced efficacy of emicizumab in an adult…
Cost-Effectiveness of Preparations Used to Stop Bleeding in Patients with AHA
Choosing the right preparation to manage acute bleeding in patients with acquired hemophilia A…
Risk of Developing Inhibitors in People with Milder Forms of Hemophilia
Moderate and mild hemophilia A differ from the severe form not only in clinical course and…
Individualized Prophylaxis with Achieving Higher Minimum Levels as a Possible Path to Optimal Treatment of Hemophilia A
Prophylactic administration of factor VIII (FVIII) concentrate is the standard of care for…
Monitoring of Joint Health is an Important Part of Hemophilia Care
Joint health has become a key aspect of the quality of life for people with hemophilia. The…
What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
Recent studies indicate that target trough levels of factor 1–3% during prophylactic treatment...
Sport and Physical Activity Benefit Hemophiliacs
Sport and physical activity are beneficial for individuals with hemophilia. This statement was…
International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
At the end of December 2020, international guidelines for COVID-19 vaccination in people with…
COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
The COVID-19 pandemic has significantly impacted nearly all medical fields. Alongside direct…
Experiences with AHA in Two Czech Centers and Risk Factor Evaluation
This summer, the journal Haemophilia published the results of an analysis of data from a…
Subscribe
Most read on this topic
Related topic
Interesting links
Most read on this topic
- International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
- Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors
Related topic
Interesting links